Dako to Offer New Antibody in U.S. to Diagnose Breast Cancer
GLOSTRUP, DENMARK -- (Marketwired) -- 04/03/13 -- Dako, an Agilent
Technologies Company and worldwide provider of cancer diagnostics,
recently received clearance from the
U.S. Food and Drug
Administration to sell FLEX Monoclonal Rabbit Anti-Human Estrogen
Receptor alpha, Clone EP1 in the United States. The clone has
available in Europe for some time and has enjoyed widespread
"We are very pleased to now be able to supply our customers in the
with this high-quality antibody for estrogen receptor
testing on Dako's Autostainer Link 48," said Karen Balstrup, global
product manager, IHC Reagents,
Research has shown that tumor growth is dependent on the presence of
progesterone or both in most breast cancers. Estrogen
receptor (ER) status in
breast carcinomas is a validated prognostic
and predictive factor for managing a patient's anti-hormonal therapy.
With this important diagnostic tool from Dako,
patients can be confident they are receiving the most
treatment for their particular type of breast cancer.
Clone EP1 shows excellent concordance with the existing ER component
ER/PR pharmDx Kit, with an overall agreement of 97.7
percent, a strong indication that pathologists can rely on the
results obtained from using this
"Clone EP1 specifically detects nuclear estrogen receptor without
staining and shows a high degree of concordance (greater
than 95 percent) to
existing clones," said Sunil S. Badve, M.D.,
Department of Pathology and Laboratory Medicine, Indiana University.
"Compared with other established ER
antibody assays this new clone is
a highly sensitive and specific antibody."
The Monoclonal Rabbit Anti-Human ER alpha, Clone EP1 was created by
Inc., using Epitomics' proprietary rabbit monoclonal
antibody technology covered
under Patent Nos. 5,675,063 and
7,402,409. Dako and Epitomics entered into a
collaboration in 2011
which allows the companies to unite competencies to provide the
anatomic pathology market with state-of-the-art antibodies.
About Dako - An Agilent Technologies Company
Dako, based in Denmark, is a global leader in tissue-based cancer
Hospital and research laboratories worldwide use Dako's
software and expertise to make accurate
diagnoses and determine the most effective treatment for cancer
patients. Dako, with 1,200 employees, operates in more than 100
countries. Dako became part of Agilent Technologies on June 21, 2012.
Information about Dako is available at www.dako.com.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world's premier
and a technology leader in chemical analysis, life
sciences, diagnostics, electronics and communications. The company's
20,500 employees serve customers
in more than 100 countries. Agilent
had revenues of $6.9 billion in fiscal 2012. Information about
Agilent is available at www.agilent.com.
Press Release pdf:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Dako Denmark A/S via Thomson Reuters ONE
Dako Denmark A/S
Maia Fredtoft Sochting
Dako Denmark A/S
Press spacebar to pause and continue. Press esc to stop.